



Impact of Behavioral and Psychosocial Factors on Relapse among Persons with Substance Use Disorder

Jawwad Muhammad Shujaat^{1*}, Muhammad Akram Riaz², Muhammad Naveed Riaz³, Masud Akhtar², Muhammad Iqbal Chaudhry⁴

¹Govt. Mian Muhammad Nawaz Sharif Associate College, Sargodha

²The University of Lahore, Sargodha Campus

³University of Sargodha, Sargodha

⁴Sargodha Campus, Superior University

* Correspondence: Dr. Jawwad Muhammad Shujaat (azmpakistan786@gmail.com)

Citation | Shujaat. M. J, Riaz. A. M, Riaz. M. N., Akhtar. M, Chaudhry. I. M, “Impact of Behavioral and Psychosocial Factors on Relapse among Persons with Substance Use Disorder”. Int. J. Innov. Sci. Technol., Special Issue pp. 50-56, 2022.

Received | July 17, 2022; **Revised** | Aug 21, 2022; **Accepted** | Aug 23, 2022; **Published** | Sep 02, 2022.

The present study was conducted to explore the impact of behavioral factors on relapse among drug addicts and moderating role of psychological factors. The study was carried out on male drug addicts from different cities in Punjab. The sample was comprised of (N = 200) male drug addicts. The sample was selected by using purposive sampling. The General Health Questionnaire, Patient Depression Questionnaire PHQ-9, Drug Abuse Screening Test-10, Perceived Stigma of Substance Abuse Scale, Adaptability, Partnership, Growth, Affection and Resolve, Alcohol Use Disorder Identification Test and The Advance Warning of Relapse Questionnaire were used in the current study. Alpha coefficients and correlation matrix for all variables were computed. Moderation analysis further revealed that perceived stigma significantly moderated the relationship between drug and alcohol abuse severity and warning of relapse. The family function also moderated the relationship between drug and alcohol abuse severity and the sign of degeneration. It was found that Perceived stigma significantly moderated the relationship between alcohol and drug abuse severity and warning of relapse.



Introduction

Addiction is defined as a psychological urge for substance use that results in clinically substantial impairment or suffering and occurs within a 12-month time frame. Tolerance, withdrawal and other symptoms are all signs of it. Around 15.9 million people take drugs all over the world and the highest concentrations are in China, the United States and Russia [1]. The reported annual prevalence of all illegal drug use in Pakistan was 6%. Pakistan has a 3.6 percent cannabis use rate compared to 2.4 percent opioid use, 1.4 percent tranquilizer use, 0.08 percent amphetamine use, 0.03 percent solvent use and 0.01 percent cocaine use. Punjab has the highest rate of intravenous drug abusers of any province, while Lahore's heroin and opium junkies have the highest rate of polydrug addiction [2]. Globally, two-thirds of addicts also suffer from a coexisting mental health condition [3]. Drug users frequently cite a desire to try new things as one of their motivations [4].

Drug addiction is one of the most stigmatized disorders in the Western world, particularly opioid addiction [5]. Stigma is the process of depreciating and discrediting others because they exhibit an undesirable attribute [6]. Drug addiction stigma hinders people from seeking and completing treatment interferes with healthcare practitioner's ability to give evidence-based therapies [7] and negatively impacts the mental and physical health of those who are stigmatized [1], [8].

The way, the public views opioid users may differ depending on the user's race, social standing, and gender as well as the person conducting the assessment. For instance, it has been observed that male opioid users are stigmatized more than female opioid users [6], whereas it was discovered that males, White people and people with lower incomes are stigmatized as opioid users less than females, non-White people and people with higher incomes [9]. The drug addict in treatment is affected by stigma in numerous kinds. Low self-esteem and mild depression are the effects. Future research could include people from a wider socioeconomic range and data from additional tertiary care hospitals and mental health facilities could be used to study a larger population. The mental health of female family members of drug addicts was found to be significantly predicted by perceived stigma and caregiver stress [10].

The current study is assimilating and extending the knowledge as well as insights that are taken from earlier research. Several studies are carried out on different variables with different gaps and their relations to each other and the selection of different samples of age and groups. The rationale for the study is basically to assess the impact of behavioral factors on relapse among drug addicts moderating the role of psychological factors.

Method

Research Design

This study examined the influence of behavioral factors, which moderate the influence of psychological factors, on relapse among drug addicts. A questionnaire was used as the survey tool for this investigation. The best tool for gathering information from the sample is a questionnaire.

Sample

The cross-sectional survey research design was used. The sample comprised two hundred drug addicts (N = 200) age ranges from 18 to onward, taken from different addiction centers in Punjab. The data was collected by using purposive sampling techniques.

Instruments

The General Health Questionnaire [11], Patient Depression Questionnaire PHQ-9 [12], Drug Abuse Screening Test-10 [13], Perceived Stigma of Substance Abuse Scale [14], Adaptability, Partnership, Growth, Affection, and Resolve [15], Alcohol Use Disorder Identification Test [16], and The Advance Warning of Relapse Questionnaire [17].

Procedure

In the present study, the ethical approval would be taken from the ethics committee of the Department of Psychology The University of the Lahore Sargodha Campus. After mandatory information and a brief introduction, the respondents filled out their informed consent form. To establish credibility, the participants were informed of the study's nature, goals and purpose. They were informed that they might withdraw their information at any time including after the scale had been completed. Informed consent was gained from the respondents before during and after the form was completed to boost their confidence and build interest in the study at hand. This was done after providing a brief introduction and any relevant instructions. The participants need to spend between 25 and 30 minutes filling out the scale, but the study was not bounded. They were encouraged by the participants' general responses and they also expressed their curiosity. The researcher scanned the scale once it has been fully completed to advert any blank or double-rated questions. The participants received thanks from the researcher for their time and willingness to take part in the study.

Results

The SPSS 26 version was used to analyze the data for the current investigation. To guarantee the scales utilized in the study had a strong psychometric foundation, participant percentages and demographic details were reviewed and alpha reliabilities were calculated. All the factors were incorporated into a correlation matrix to get a better understanding of the relationship structure. The testing of the hypothesis involved regression analysis. To compare these scales based on demographic factors. An independent sample t-test was carried out. Following analysis with SPSS-23, the following results were discovered.

Table 1. Moderation of PSAS between GHQ and AWARE.

| Model | B | β | SE | Model | B | β | SE |
|-------------------|----------|---------|-----|-------------------|----------|---------|-------|
| Constant | 80.93*** | | 1.1 | Constant | 79.43*** | | 1.04 |
| GHQ | -1.4 | -.08 | 1.4 | GHQ | 6.57*** | .39*** | 11.04 |
| PSAS | -6.0*** | -.36*** | 1.1 | PSAS | -7.98*** | -.47*** | 1.03 |
| GHQ \times PSAS | 3.1 | .22 | 1.2 | PHQ \times PSAS | 5.74 | .28 | 1.21 |
| R ² | .19 | | | R ² | .36 | | |
| ΔR^2 | .02 | | | ΔR^2 | .07 | | |

Note. GHQ = General Health Questionnaire, PHQ = Physical Health Questionnaire, DAST = Drug Abuse Screening test, APGAR = Adaptability, Partnership, Growth, Affection and Resolve Scale, PSAS = Perceived Stigma of Substance Abuse Scale, AUDIT = Alcohol Use Disorder Identification Test, AWARE = Advance Warning of Relapse.

*** $p < .001$

Results indicated that GHQ negatively predicts AWARE ($\beta = -.08, p < .001$) and APGAR ($\beta = -.36, p < .001$) negatively indicates AWARE, and GHQ \times APGAR positively predicts Aware ($\beta = .22, p < .01$). The ΔR^2 value of .02 indicated 2% change in the variance of the model with $\Delta F(1, 188) = 6.722, p < .001$. Findings show that PSAS moderates the relation between GHQ and AWARE. Results indicated that PHQ negatively predicts AWARE ($\beta = .39, p < .001$) and APGAR ($\beta = -.47, p < .001$) negatively predicts Aware. GHQ \times APGAR positively predicts Aware ($\beta = .28, p < .01$). The ΔR^2 value of .07 indicated a 7% change in the variance of the model with $\Delta F(1, 188) = 22.45, p < .001$. Results indicated that PSAS moderates the relation between PHQ and AWARE.




Figure 1. Mod-Graph with Moderating effect of PSAS between GHQ and AWARE.




Figure 2. Mod-Graph with Moderating effect of PSAS between PHQ and AWARE.

Table 3. Moderation of PSAS between DAST and AWARE.

| Model | B | β | SE | Model | B | β | SE |
|----------------|----------|---------|------|----------------|----------|---------|------|
| Constant | 81.45*** | | 1.14 | Constant | 81.34*** | | .94 |
| DAST | -.89 | -.05 | 1.57 | DAST | -1.47** | -.09** | .94 |
| PSAS | -5.6*** | -.38*** | 1.14 | PSAS | -4.23*** | -.25*** | .95 |
| AUDIT × PSAS | 1.30 | .08 | 1.53 | DAST × PSAS | 11.49 | .52 | 1.26 |
| PSAS | | | | | | | |
| R ² | .12 | | | R ² | .39 | | |
| ΔR^2 | .00 | | | ΔR^2 | .27 | | |

Note. GHQ = General Health Questionnaire, PHQ = Physical Health Questionnaire, DAST = Drug Abuse Screening test, APGAR = Adaptability, Partnership, Growth, Affection and Resolve Scale, PSAS = Perceived Stigma of Substance Abuse Scale, AUDIT = Alcohol Use Disorder Identification Test, AWARE = Advance Warning of Relapse.

*** $p < .001$

Results indicated that DAST negatively predicts AWARE ($\beta = -.05, p < .001$) and PSAS ($\beta = -.38, p < .001$) negatively predicts Aware. DAST × PSAS positively predicted Aware ($\beta = .08,$

$p < .01$). The ΔR^2 value of .00 indicated a 0% change in the variance of the model with $\Delta F(1, 188) = .71, p < .001$. Findings show that PSAS moderates the relation between DAST and AWARE. Results indicated that AUDIT negatively predicts AWARE ($\beta = -.09, p < .001$) and PSAS ($\beta = -.25, p < .001$) negatively predicts Aware, and $AUDIT \times AWARE$ positively predicts Aware ($\beta = .52, p < .01$). The ΔR^2 value of .27 indicated 27% change in the variance of the model with $\Delta F(1, 188) = 83.26, p < .001$. Results indicated that AUDIT moderates the relation between PSAS and AWARE.




Figure 3. Mod-Graph with Moderating effect of PSAS between DAST and AWARE.




Figure 4. Mod-Graph with Moderating effect of PSAS between AUDIT and AWARE.

Discussion

Moderation analysis revealed that perceived stigma significantly moderated the relationship between drug and alcohol abuse severity and warning of relapse. People who have been diagnosed with both substance use disorder and schizophrenia spectrum disorder have a direct and indirect link between self-stigma and relapse deterioration, which is consistent with earlier studies linking self-stigma to poorer self-esteem in people with either illness alone [18], [19]. Improved self-esteem has been demonstrated to be a significant benefit of stigma reduction, whereas lower self-esteem has been connected to non-compliance with treatment

and relapses, delaying recovery. When faced with a challenge or danger, the brain's information processing circuits that are responsible for interpreting both internal and external environmental stimuli as well as cognitive and emotional inputs, such as the primary sensory projections and sensory association cortices, are active. Individuals are motivated to adopt or minimize stress by coping methods when faced with risk, threat, or a problematic situation [20].

References

- [1] S. Khan, "Abuse Drug Addictive's: Beginning and Causes of Drug among Different Gender in District Charsadda, Pakistan," *J. Alcohol. Drug Abus. Subst. Depend.*, vol. 7, no. 1, pp. 1–4, Jun. 2021, doi: 10.24966/ADSD-9594/100023.
- [2] M. Ali and N. S. Goraya, "Increasing Trend of Substance Using among Females of Punjab," *Pakistan J. Public Heal.*, vol. 11, no. 3, pp. 194–200, Oct. 2021, doi: 10.32413/PJPH.V11I3.759.
- [3] T. Rahman, M. D. G. Hasnain, and A. Islam, "Food insecurity and mental health of women during COVID-19: Evidence from a developing country," *PLoS One*, vol. 16, no. 7, p. e0255392, Jul. 2021, doi: 10.1371/JOURNAL.PONE.0255392.
- [4] D. L. Biancarelli *et al.*, "Strategies used by people who inject drugs to avoid stigma in healthcare settings," *Drug Alcohol Depend.*, vol. 198, no. January 2021, pp. 80–86, 2019, doi: 10.1016/j.drugalcdep.2019.01.037.
- [5] N. Topkaya, E. Şahin, A. K. Krettmann, and C. A. Essau, "Stigmatization of people with alcohol and drug addiction among Turkish undergraduate students," *Addict. Behav. Reports*, vol. 14, no. October, 2021, doi: 10.1016/j.abrep.2021.100386.
- [6] E. Wood and M. Elliott, "Opioid Addiction Stigma: The Intersection of Race, Social Class, and Gender," <https://doi.org/10.1080/10826084.2019.1703750>, vol. 55, no. 5, pp. 818–827, Mar. 2019, doi: 10.1080/10826084.2019.1703750.
- [7] J. Wogen and M. T. Restrepo, "Human Rights, Stigma, and Substance Use," *Health Hum. Rights*, vol. 22, no. 1, p. 51, Jun. 2020, Accessed: Aug. 22, 2022. [Online]. Available: /pmc/articles/PMC7348456/
- [8] K. Goodyear and D. Chavanne, "Sociodemographic Characteristics and the Stigmatization of Prescription Opioid Addiction," *J. Addict. Med.*, vol. 14, no. 2, pp. 150–155, Mar. 2020, doi: 10.1097/ADM.0000000000000552.
- [9] D. Wasserman, M. Iosue, A. Wuestefeld, and V. Carli, "Adaptation of evidence-based suicide prevention strategies during and after the COVID-19 pandemic," *World Psychiatry*, vol. 19, no. 3, pp. 294–306, Oct. 2020, doi: 10.1002/WPS.20801.
- [10] S. Vadher *et al.*, "Burden of care in caregivers of patients with alcohol use disorder and schizophrenia and its association with anxiety, depression and quality of life," *Gen. Psychiatry*, vol. 33, no. 4, pp. 1–9, 2020, doi: 10.1136/gpsych-2020-100215.
- [11] D. P. Goldberg and V. F. Hillier, "A scaled version of the General Health Questionnaire," *Psychol. Med.*, vol. 9, no. 1, pp. 139–145, 1979, doi: 10.1017/S0033291700021644.
- [12] R. L. Spitzer *et al.*, "Utility of a New Procedure for Diagnosing Mental Disorders in Primary Care: The PRIME-MD 1000 Study," *JAMA J. Am. Med. Assoc.*, vol. 272, no. 22, pp. 1749–1756, 1994, doi: 10.1001/jama.1994.03520220043029.
- [13] "Instrument: Drug Abuse Screening Test (DAST-10) | NIDA CTN Common Data Elements." <https://cde.drugabuse.gov/instrument/e9053390-ee9c-9140-e040-bb89ad433d69> (accessed Aug. 22, 2022).
- [14] J. B. Luoma, A. K. O'Hair, B. S. Kohlenberg, S. C. Hayes, and L. Fletcher, "The Development and Psychometric Properties of a New Measure of Perceived Stigma Toward Substance Users," *Subst. Use Misuse*, vol. 45, no. 1–2, p. 47, 2010, doi:

- 10.3109/10826080902864712.
- [15] G. Smilkstein, "The family APGAR: a proposal for a family function test and its use by physicians.," *J. Fam. Pract.*, vol. 6, no. 6, pp. 1231–1239, 1978.
- [16] M. Piccinelli, "Alcohol use disorders identification test (AUDIT)," *Epidemiol. Psychiatr. Soc.*, vol. 7, no. 1, pp. 70–73, 1998, doi: 10.1017/S1121189X00007144.
- [17] T. T. Gorski and M. Miller, "Counseling for relapse prevention," p. 143, 1982.
- [18] K. Park, L. MinHwa, and M. Seo, "The impact of self-stigma on self-esteem among persons with different mental disorders," *Int. J. Soc. Psychiatry*, vol. 65, no. 7–8, pp. 558–565, Nov. 2019, doi: 10.1177/0020764019867352.
- [19] K. A. Crapanzano, R. Hammarlund, B. Ahmad, N. Hunsinger, and R. Kullar, "The association between perceived stigma and substance use disorder treatment outcomes: a review," *Subst. Abuse Rehabil.*, vol. 10, pp. 1–12, Dec. 2018, doi: 10.2147/SAR.S183252.
- [20] H. A. Demirtaş-Madran, "Accepting Restrictions and Compliance With Recommended Preventive Behaviors for COVID-19: A Discussion Based on the Key Approaches and Current Research on Fear Appeals," *Front. Psychol.*, vol. 12, no. June, pp. 1–15, 2021, doi: 10.3389/fpsyg.2021.558437.



Copyright © by authors and 50Sea. This work is licensed under Creative Commons Attribution 4.0 International License.